• 1
    Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853860.
  • 2
    Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society–USA Panel. JAMA 2002; 288: 222235.
  • 3
    Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354: 11121115.
  • 4
    Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000; 22: 685708.
  • 5
    Walker UA, Setzer B, Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 2002; 16: 21652173.
  • 6
    Gaou I, Malliti M, Guimont MC, Letteron P, Demeilliers C, Peytavin I, Degott C, et al. Effect of stavudine on mitochondrial genome and fatty acid oxidation in lean and obese mice. J Pharmacol Exp Ther 2001; 297: 516523.
  • 7
    Gerschenson M, Nguyen VT, St Claire MC, Harbaugh SW, Harbaugh JW, Proia LA, Poirier MC. Chronic stavudine exposure induces hepatic mitochondrial toxicity in adult Erythrocebus patas monkeys. J Hum Virol 2001; 4: 335342.
  • 8
    Brivet FG, Nion I, Megarbane B, Slama A, Brivet M, Rustin P, Munnich A. Fatal lactic acidosis and liver steatosis associated with didanosine and stavudine treatment: a respiratory chain dysfunction? J Hepatol 2000; 32: 364365.
  • 9
    Chariot P, Drogou I, de Lacroix-Szmania I, Eliezer-Vanerot MC, Chazaud B, Lombes A, Schaeffer A, et al. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol 1999; 30: 156160.
  • 10
    Gerard Y, Maulin L, Yazdanpanah Y, Tribonniere X, Amiel C, Maurage CA, Robin S, et al. Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. AIDS 2000; 14: 27232730.
  • 11
    John M, Mallal S. Hyperlactatemia syndromes in people with HIV infection. Curr Opin Infect Dis 2002; 15: 2329.
  • 12
    Leclercq P, Roth H, Bosseray A, Leverve X. Investigating lactate metabolism to estimate mitochondrial status. Antivir Ther 2003; 6(Suppl. 4): 16.
  • 13
    Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372374.
  • 14
    Walker UA, Bickel M, Lütke Volksbeck SI, Ketelsen UP, Schofer H, Setzer B, Venhoff N, et al. Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J Acquir Immune Defic Syndr 2002; 29: 117121.
  • 15
    Hammond EL, Sayer D, Nolan D, Walker UA, Ronde A, Montaner JS, Cote HC, et al. Assessment of precision and concordance of quantitative mitochondrial DNA assays: a collaborative international quality assurance study. J Clin Virol 2003; 27: 97110.
  • 16
    Thiers V, Jaffredo F, Tuveri R, Chodan N, Brechot C. Development of a simple restriction fragment length polymorphism (RFLP) based assay for HCV genotyping and comparative analysis with genotyping and serotyping tests. J Virol Methods 1997; 65: 917.
  • 17
    Barbaro G, Di Lorenzo G, Asti A, Ribersani M, Belloni G, Grisorio B, Filice G, et al. Hepatocellular mitochondrial alterations in patients with chronic hepatitis C: ultrastructural and biochemical findings. Am J Gastroenterol 1999; 94: 21982205.
    Direct Link:
  • 18
    Rust C, Gores GJ. Does hepatitis C cause liver injury by pathways associated with mitochondrial dysfunction? Am J Gastroenterol 1999; 94: 20032005.
    Direct Link:
  • 19
    Attardi G, Yoneda M, Chomyn A. Complementation and segregation behavior of disease-causing mitochondrial DNA mutations in cellular model systems. Biochim Biophys Acta 1995; 1271: 241248.
  • 20
    Moraes CT, Ricci E, Petruzzella V, Shanske S, DiMauro S, Schon EA, Bonilla E. Molecular analysis of the muscle pathology associated with mitochondrial DNA deletions. Nature Genet 1992; 1: 359367.
  • 21
    Mandel H, Hartman C, Berkowitz D, Elpeleg ON, Manov I, Iancu TC. The hepatic mitochondrial DNA depletion syndrome: ultrastructural changes in liver biopsies. HEPATOLOGY 2001; 34: 776784.
  • 22
    John M, Moore CB, James IR, Nolan D, Upton RP, McKinnon EJ, Mallal SA. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001; 15: 717723.
  • 23
    Olano JP, Borucki MJ, Wen JW, Haque AK. Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine. Clin Infect Dis 1995; 21: 973976.
  • 24
    Vittecoq D, Jardel C, Barthelemy C, Escaut L, Cheminot N, Chapin S, Sternberg D, et al. Mitochondrial damage associated with long-term antiretroviral treatment: associated alteration or causal disorder? J Acquir Immune Defic Syndr 2002; 31: 299308.